Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Non-Current Assets (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Other Non-Current Assets over the past 3 years, most recently at $2.2 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $2.2 million for Q4 2025, up 128.71% from a year ago — trailing twelve months through Dec 2025 was $2.2 million (up 128.71% YoY), and the annual figure for FY2025 was $2.2 million, up 128.71%.
  • Other Non-Current Assets for Q4 2025 was $2.2 million at Tonix Pharmaceuticals Holding, up from $1.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for TNXP hit a ceiling of $2.2 million in Q4 2025 and a floor of $292000.0 in Q2 2023.
  • Median Other Non-Current Assets over the past 3 years was $955500.0 (2024), compared with a mean of $999583.3.
  • Peak annual rise in Other Non-Current Assets hit 229.11% in 2024, while the deepest fall reached 15.77% in 2024.
  • Tonix Pharmaceuticals Holding's Other Non-Current Assets stood at $1.1 million in 2023, then fell by 15.77% to $951000.0 in 2024, then soared by 128.71% to $2.2 million in 2025.
  • The last three reported values for Other Non-Current Assets were $2.2 million (Q4 2025), $1.3 million (Q3 2025), and $931000.0 (Q2 2025) per Business Quant data.